ADC Therapeutics SA: ADC Therapeutics Announces Exclusive Li

ADC Therapeutics to receive $30 million upfront payment, up to $205 million in milestones, and double-digit royalties based on net sales in Japan ADC Therapeutics SA (NYSE: ADCT), a commercial-stage

Related Keywords

China , Japan , United States , New Jersey , Switzerland , London , City Of , United Kingdom , Singapore , Japanese , Lausanne Biop , Mary Ann Ondish , Eugenia Litz , Amanda Hamilton , Hiroaki Ueno , Chris Martin , Linkedin , Company On Twitter , Mitsubishi Tanabe Pharma Corporation , Drug Administration , Exchange Commission , European Medicines Agency , Overland Pharmaceuticals , Committee For Medicinal Products Human Use , Dynamics Group , Chief Executive Officer , Mitsubishi Tanabe Pharma , Marketing Authorization Application , Medicinal Products , Human Use , Orphan Drug , San Francisco Bay Area , Ann Ondish , Therapeutics , Nnounces , Exclusive , License , Mitsubishi , Watanabe , Dharma , Corporation , Evelop , Ommercialize , Zynlonta , Loncastuximab , Esirine , Spyl ,